Hepatocyte growth factor is positively associated with risk of stroke: The MESA (Multi-Ethnic Study of Atherosclerosis)

Stroke

Volumn 47, Issue 11, 2016, Pages 2689-2694

  Bell, Elizabeth J ^a   Larson, Nicholas B ^a   Decker, Paul A ^a   Pankow, James S ^b   Tsai, Michael Y ^c   Hanson, Naomi Q ^c   Wassel, Christina L ^d   Longstreth, W T ^e   Bielinski, Suzette J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

atherosclerosis; epidemiology; hepatocyte growth factor; incidence; risk factors; stroke

Indexed keywords

SCATTER FACTOR; BIOLOGICAL MARKER; HGF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; DISEASE FREE SURVIVAL; ETHNIC DIFFERENCE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY ANALYSIS; STROKE RISK; BLOOD; STROKE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOMARKERS; BRAIN ISCHEMIA; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; STROKE; UNITED STATES;

EID: 84992723900     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.014172     Document Type: Article

References (25)

1. Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond). 2015;129:1173-1193. doi: 10.1042/CS20150502.
2. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28:409-413.
3. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun. 1998;242:238-243.
4. Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens. 1998;16(12 pt 2):2019-2026.
5. Nakano N, Moriguchi A, Morishita R, Kida I, Tomita N, Matsumoto K, et al. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension. 1997;30:1448-1454.
6. Lamblin N, Susen S, Dagorn J, Mouquet F, Jude B, Van Belle E, et al. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J. 2005;150:137-143. doi: 10.1016/j.ahj.2005.03.047.
7. Yamamoto Y, Kohara K, Tabara Y, Miki T. Association between carotid arterial remodeling and plasma concentration of circulating hepatocyte growth factor. J Hypertens. 2001;19:1975-1979.
8. Susen S, Sautière K, Mouquet F, Cuilleret F, Chmaït A, McFadden EP, et al. Serum hepatocyte growth factor levels predict long-Term clinical outcome after percutaneous coronary revascularization. Eur Heart J. 2005;26:2387-2395. doi: 10.1093/eurheartj/ehi436.
9. Rajpathak SN, Wassertheil-Smoller S, Crandall J, Liu S, Ho GY. Hepatocyte growth factor and clinical diabetes in postmenopausal women. Diabetes Care. 2010;33:2013-2015. doi: 10.2337/dc10-0710.
10. Lieb W, Safa R, Benjamin EJ, Xanthakis V, Yin X, Sullivan LM, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J. 2009;30:1121-1127. doi: 10.1093/eurheartj/ehp007.
11. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, et al. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol. 2003;41:1408-1413.
12. Bancks MP, Bielinski SJ, Decker PA, Hanson NQ, Larson NB, Sicotte H, et al. Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism. 2016;65:64-72. doi: 10.1016/j. metabol.2015.10.023.
13. Anan F, Masaki T, Jikumaru K, Iwao T, Eshima N, Saikawa T, et al. Hepatocyte growth factor is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients. Eur J Clin Invest. 2010;40:585-590. doi: 10.1111/j.1365-2362.2010.02301.x.
14. Anan F, Shimomura T, Imagawa M, Masaki T, Nawata T, Takahashi N, et al. Predictors for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism. 2007;56:593-598. doi: 10.1016/j.metabol.2007.01.003.
15. Matsumori A, Takano H, Obata JE, Takeda S, Tsuyuguchi N, Ono K, et al. Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction. Circ J. 2002;66:216-218.
16. Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, McGinn AP, et al. Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. Stroke. 2010;41:857-862. doi: 10.1161/STROKEAHA.109.567719.
17. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881.
18. Kawasaki R, Xie J, Cheung N, Lamoureux E, Klein R, Klein BE, et al; MESA. Retinal microvascular signs and risk of stroke: the Multi-Ethnic Study of Atherosclerosis (MESA). Stroke. 2012;43:3245-3251. doi: 10.1161/STROKEAHA.112.673335.
19. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29:1037-1057. doi: 10.1002/sim.3841.
20. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun. 1995;215:483-488.
21. Silvagno F, Follenzi A, Arese M, Prat M, Giraudo E, Gaudino G, et al. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol. 1995;15:1857-1865.
22. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension. 1999;33:1379-1384.
23. Morishita R, Aoki M, Yo Y, Ogihara T. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J. 2002;49:273-284.
24. Larson NB, Berardi C, Decker PA, Wassel CL, Kirsch PS, Pankow JS, et al. Trans-ethnic meta-Analysis identifies common and rare variants associated with hepatocyte growth factor levels in the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Hum Genet. 2015;79:264-274. doi: 10.1111/ahg.12119.
25. Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, Rohan TE, et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev. 2007;16:1291-1293. doi: 10.1158/1055-9965.EPI-06-1089.